全文获取类型
收费全文 | 38664篇 |
免费 | 2243篇 |
国内免费 | 572篇 |
专业分类
耳鼻咽喉 | 217篇 |
儿科学 | 789篇 |
妇产科学 | 559篇 |
基础医学 | 2286篇 |
口腔科学 | 405篇 |
临床医学 | 3341篇 |
内科学 | 4989篇 |
皮肤病学 | 610篇 |
神经病学 | 1478篇 |
特种医学 | 598篇 |
外科学 | 2343篇 |
综合类 | 3989篇 |
现状与发展 | 1篇 |
预防医学 | 5244篇 |
眼科学 | 326篇 |
药学 | 10932篇 |
12篇 | |
中国医学 | 755篇 |
肿瘤学 | 2605篇 |
出版年
2023年 | 616篇 |
2022年 | 1130篇 |
2021年 | 1446篇 |
2020年 | 1350篇 |
2019年 | 1703篇 |
2018年 | 1623篇 |
2017年 | 1260篇 |
2016年 | 1040篇 |
2015年 | 1221篇 |
2014年 | 2784篇 |
2013年 | 3418篇 |
2012年 | 2485篇 |
2011年 | 2818篇 |
2010年 | 2060篇 |
2009年 | 1959篇 |
2008年 | 1940篇 |
2007年 | 1794篇 |
2006年 | 1491篇 |
2005年 | 1206篇 |
2004年 | 957篇 |
2003年 | 762篇 |
2002年 | 585篇 |
2001年 | 537篇 |
2000年 | 476篇 |
1999年 | 479篇 |
1998年 | 304篇 |
1997年 | 289篇 |
1996年 | 231篇 |
1995年 | 257篇 |
1994年 | 249篇 |
1993年 | 167篇 |
1992年 | 156篇 |
1991年 | 108篇 |
1990年 | 110篇 |
1989年 | 89篇 |
1988年 | 106篇 |
1987年 | 96篇 |
1986年 | 100篇 |
1985年 | 201篇 |
1984年 | 254篇 |
1983年 | 174篇 |
1982年 | 196篇 |
1981年 | 169篇 |
1980年 | 172篇 |
1979年 | 145篇 |
1978年 | 135篇 |
1977年 | 122篇 |
1976年 | 115篇 |
1975年 | 136篇 |
1974年 | 79篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Research in social & administrative pharmacy》2022,18(8):3284-3289
BackgroundAdverse drug reactions (ADRs) and adverse drug events (ADEs) in older people contribute to a significant proportion of hospital admissions and are common following discharge. Effective interventions are therefore required to combat the growing burden of preventable ADRs. The Prediction of Hospitalisation due to Adverse Drug Reactions in Elderly Community Dwelling Patients (PADR-EC) score is a validated risk score developed to assess the risk of ADRs in people aged 65 years and older and has the potential to be utilised as part of an intervention to reduce ADRs.ObjectivesThis trial was designed to investigate the effectiveness of an intervention to reduce ADR incidence in older people and to obtain further information about ADRs and ADEs in the 12–24 months following hospital discharge.MethodsThe study is an open-label randomised-controlled trial to be conducted at the Royal Hobart Hospital, a 500-bed public hospital in Tasmania, Australia. Community-dwelling patients aged 65 years and older with an unplanned overnight admission to a general medical ward will be recruited. Following admission, the PADR-EC ADR score will be calculated by a research pharmacist, with the risk communicated to clinicians and discussed with participants. Following discharge, nominated general practitioners and community pharmacists will receive the risk score and related medication management advice to guide their ongoing care of the patient. Follow-up with participants will occur at 3 and 12 and 18 and 24 months to identify ADRs and ADEs. The primary outcome is moderate-severe ADRs at 12 months post-discharge, and will be analysed using the cumulative incidence proportion, survival analysis and Poisson regression.SummaryIt is hypothesised that the trial will reduce ADRs and ADEs in the intervention population. The study will also provide valuable data on post-discharge ADRs and ADEs up to 24 months post-discharge. 相似文献
4.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(1):151-159
Background & aimsTo determine the trends of self-reported non-adherence rates among adults taking Type 2 medicines (T2D) medicines between 2017 and 2019 and to identify the patterns for the frequently reported reasons for non-adherence in the United States.Methods & resultsData from the National Health and Wellness Survey, a self-administered, internet-based cross-sectional survey of US adults from 2017 to 2019 was used. Non-adherence was measured using the self-reported Medication Adherence Reasons Scale (MAR-Scale). Frequencies were used to identify the reasons for non-adherence for insulin and non-insulin therapies for T2D.Data were obtained from 2983 respondents in 2017, 5416 in 2018, and 5268 in 2019. Based on the MAR-Scale, the self-reported medication non-adherence rate was 25% in 2017, 21% in 2018, and 27% in 2019. The most common reason for non-adherence across all the three years was simple forgetfulness, yet patients reported the lowest mean number of days missing medication for that reason. Though less frequently reported, non-adherence lasted longer when patient did not know how to take their medicines, cost was a reason, or had concerns about the long term effects of the medicines.ConclusionsWith no significant improvement in adherence with T2D medicines over time, regardless of better awareness and extensive diabetes education, focus should be on individualized non-adherence reasons-based interventions. 相似文献
5.
美国食品药品管理局(FDA)于2022年7月发布了"治疗等效性评价供企业用指导原则"(草案)。该指导原则阐明了FDA治疗等效性的标准以及治疗等效性编码系统,目的是准确评价仿制药与参比制剂的治疗等效性并通过治疗等效性代码,在"橙皮书"中迅速检索到治疗等效的仿制药。而中国目前尚无类似的指导原则,详细介绍FDA该指导原则主要内容,期望对中国加强仿制药的治疗等效性评价和加速完善和实施符合国情的治疗等效性编码系统有所帮助。 相似文献
6.
7.
目的 评价美国国家电器制造协会(National Electrical Manufactures Association, NEMA)最新标准(NU 2-2018)在正电子发射型计算机断层显像/电子计算机断层显像(positron emission tomography/computed tomography, PET/CT)设备性能检测中的作用。 方法 依据最新的NEMA NU 2-2018标准,检测西门子Biograph Vision PET/CT的空间分辨率、灵敏度、散射分数、计数丢失、随机符合、飞行时间分辨率、计数丢失率和随机符合校正精度、图像质量、衰减和散射校正精度及PET与CT配准精度指标。 结果 距视野中心1 cm处横向和轴向空间分辨率分别为3.75 mm和3.76 mm;在视野中心和轴向10 cm处的灵敏度分别为16.83 kcps/MBq和16.67 kcps/MBq;放射性浓度为27.37 kBq/mL时,最大等效噪声计数率为258.26 kcps,散射分数为38.58%;系统时间分辨率为209.82 ps;图像质量模型的对比度恢复系数范围为88.9%~96.2%,背景变异系数范围为2.05%~6.80%,平均肺插件残余误差为2.43%;计数丢失和随机符合校正最大误差为3.9%;距离床板末端 5 cm 和 100 cm处,在距视野中心Y轴1 cm处,PET和CT的配准精度分别为0.46 mm和1.07 mm,在距视野中心X轴20 cm处,PET和CT的配准精度分别为1.06 mm和1.45 mm,在距视野中心Y轴20 cm处PET和CT的配准精度分别为0.85 mm和1.15 mm。 结论 NEMA NU 2-2018标准检测条件更加接近临床,能更好地反映PET/CT设备的系统性能。 相似文献
8.
9.
《American journal of surgery》2023,225(1):113-117
BackgroundRacial disparities in extracorporeal membrane oxygenation (ECMO) outcomes in patients with a broad set of indications are not well documented.MethodsAdults requiring ECMO were identified in the 2016–2019 National Inpatient Sample. Patient and hospital characteristics, including mortality, clinical outcomes, and resource utilization were analyzed using multivariable regressions.ResultsOf 43,190 adult ECMO patients, 67.8% were classified as White, 18.1% Black, and 10.4% Hispanic. Although mortality for Whites declined from 47.5 to 41.0% (P = 0.002), it remained steady for others. Compared to White, Asian/Pacific Islander (PI) race was linked to increased odds of mortalty (AOR = 1.4, 95% CI = 1.1–2.0). Black race was associated with increased odds of acute kidney injury (AOR = 1.4, 95%-CI: 1.2–1.7), while Hispanic race was linked to neurologic complications (AOR 21.6; 95% CI 1.2–2.3). Black and Hispanic race were also associated with increased incremental costs.ConclusionsRace-based disparities in ECMO outcomes persist in the United States. Further work should aim to understand and mitigate the underlying reasons for such findings. 相似文献
10.